NASDAQ: IRMDIradimed Corp Stock
$60.48+0.14 (+0.23%)
Updated Jan 24, 2025
IRMD Price
$60.48
Fair Value Price
$42.39
Market Cap
$766.49M
52 Week Low
$40.18
52 Week High
$61.00
P/E
40.86x
P/B
9.19x
P/S
8.94x
PEG
6.79x
Dividend Yield
0.74%
Revenue
$71.31M
Earnings
$18.63M
Gross Margin
77.1%
Operating Margin
33.12%
Profit Margin
26.1%
Debt to Equity
0.13
Operating Cash Flow
$24M
Beta
0.85
Next Earnings
Feb 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
IRMD Overview
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IRMD's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
A
Sentiment
C
Safety
A
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
D
IRMD
Ranked#13 of 128
Ranked#13 of 128
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $33.49 | A | |
| $17.39 | A | |
| $7.14 | A |
Be the first to know about important IRMD news, forecast changes, insider trades & much more!
IRMD News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IRMD scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IRMD ($60.48) is overvalued by 42.66% relative to our estimate of its Fair Value price of $42.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IRMD ($60.48) is not significantly undervalued (42.66%) relative to our estimate of its Fair Value price of $42.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IRMD ($60.48) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more IRMD due diligence checks available for Premium users.
Valuation
IRMD fair value
Fair Value of IRMD stock based on Discounted Cash Flow (DCF)
Price
$60.48
Fair Value
$42.39
Overvalued by
42.66%
IRMD ($60.48) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IRMD ($60.48) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IRMD ($60.48) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IRMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
40.86x
Industry
40.61x
Market
30.33x
IRMD is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
IRMD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
IRMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.19x
Industry
4.3x
IRMD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IRMD price to earnings growth (PEG)
For valuing profitable companies with growth potential
IRMD is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
IRMD's financial health
Profit margin
Revenue
$18.3M
Net Income
$5.0M
Profit Margin
27.6%
IRMD's Earnings (EBIT) of $23.61M... subscribe to Premium to read more.
Interest Coverage Financials
IRMD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$94.2M
Liabilities
$10.8M
Debt to equity
0.13
IRMD's short-term assets ($74.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRMD's short-term assets ($74.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IRMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$9.1M
Investing
-$4.0M
Financing
-$1.9M
IRMD's operating cash flow ($23.55M)... subscribe to Premium to read more.
Debt Coverage Financials
IRMD vs Medical Device Stocks
Iradimed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.